Dexcom Looks To Expansion, Operational Efficiency For Rapid Growth
Executive Summary
Continuous blood glucose monitoring specialist Dexcom has seen its sales soar from $60m to over $700m within five years or so. Company president and CEO Kevin Sayer told Medtech Insight how the company is aiming to maintain this upward trajectory with a new addition to the leadership team, increased operational efficiency and expansion into new markets.